There is still a lot we don’t know when it comes to GLP-1s. How do these drugs’ side effects vary across different patients? How effective are these medications in the long term? Are barriers to ...

OMNY, a national data ecosystem that covers 75 million lives, is launching a GLP-1 (glucagon-like peptide) database. The drug specific data resource is the first of its kind for the company as OMNY ...

A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...

Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for weight loss or diabetes management doesn ’t raise the risk for adverse psychiatric events and improves quality of life (QOL) in ...

Exclusive data from Nasdaq and Komodo Health is giving investors critical insights into one of the most popular technological developments in years: the diabetes and weight loss drugs known as GLP-1 ...